Klinikum Ernst von Bergmann gGmbH

The clinic’s program in Digestive System Diseases concentrates on inflammatory bowel disorders, cystic fibrosis and colorectal malignancies, aiming to test innovative therapies and improve long‑term outcomes.

• Evaluation of novel biologics for ulcerative colitis remission
• Assessment of new oral agents targeting Crohn’s disease activity
• Long‑term safety of triple‑combination therapy for cystic fibrosis
• Adjuvant treatment strategies after resection of stage II colon and rectal cancer

Researchers at Klinikum Ernst von Bergmann gGmbH collaborate with national networks to accelerate therapeutic advances for patients in Potsdam and beyond.

In the area of Hemic and Lymphatic Diseases, the site explores targeted and immune‑based regimens for blood cancers and lymphomas, seeking to enhance survival while reducing toxicity.

• Targeted inhibitor studies for acute myeloid leukemia
• Checkpoint‑inhibitor combinations for classical Hodgkin lymphoma
• Novel chemotherapy‑free protocols for Philadelphia‑positive acute lymphoblastic leukemia
• Maintenance approaches after curative therapy for advanced-stage Hodgkin lymphoma

The department leverages its expertise in hematology to offer patients access to cutting‑edge clinical investigations.

The department’s work on Immune System Diseases and related phenomena focuses on modulating dysregulated immunity, testing new biologics and combination strategies across autoimmune conditions.

• Head‑to‑head trials of anti‑IL‑23 versus standard immunosuppression in ulcerative colitis
• Combination of a novel anti‑IL‑17 agent with metabolic therapy for obesity‑related inflammation
• Immune‑phenotype guided dosing of checkpoint inhibitors in solid tumors
• Safety profiling of long‑term biologic use in chronic inflammatory bowel disease

By integrating immunological biomarkers, the site strives to personalize treatment for patients with autoimmune and inflammatory disorders.

Research on Neoplasms at the clinic encompasses breast, lung and head‑and‑neck cancers, with a strong emphasis on novel targeted agents and immunotherapies to prevent recurrence.

• Neoadjuvant checkpoint blockade combined with chemotherapy for triple‑negative breast cancer
• HER2‑targeted antibody‑drug conjugates in early‑stage HER2‑positive breast cancer
• PD‑L1 directed therapy for high‑expressing non‑small cell lung cancer
• De‑intensified adjuvant treatment after transoral surgery for HPV‑positive oropharyngeal cancer

The site’s multidisciplinary team collaborates with oncology centers across Germany to bring innovative cancer trials to the local community.

In the field of Nervous System Diseases, investigators are evaluating acute stroke therapies and auditory nerve recovery, aiming to improve functional outcomes after sudden events.

• Single‑dose thrombolytic agent versus standard care in acute ischemic stroke
• Intratympanic injection of a novel compound for idiopathic sudden sensorineural hearing loss
• Neuro‑imaging biomarkers to predict response to reperfusion therapy
• Safety monitoring of adjunctive neuroprotective agents in stroke patients

These studies provide rapid access to emerging treatments for patients experiencing acute neurological emergencies in Potsdam.

The clinic’s otorhinolaryngology program addresses Otorhinolaryngologic Diseases such as HPV‑related head‑and‑neck tumors and sudden hearing loss, testing less invasive therapeutic pathways.

• Reduced‑intensity adjuvant radiotherapy after transoral resection of HPV‑positive oropharyngeal cancer
• Combination of systemic immunotherapy with surgery for early‑stage head‑and‑neck carcinoma
• Evaluation of a novel middle‑ear injection for rapid auditory recovery
• Quality‑of‑life assessments following organ‑preserving treatment approaches

By integrating surgical innovation with systemic therapy, the site seeks to preserve function while maintaining oncologic control.

Studies in Respiratory Tract Diseases focus on chronic airway disorders and thoracic malignancies, exploring both antimicrobial and immunotherapeutic options.

• Bronchiectasis trial comparing a new anti‑inflammatory agent with standard care
• Checkpoint inhibitor plus chemotherapy for limited‑stage small cell lung cancer
• High‑PD‑L1 non‑small cell lung cancer treatment with a novel PD‑L1 inhibitor
• Biomarker‑driven maintenance therapy after curative resection of early‑stage lung cancer

The respiratory research program collaborates closely with pulmonology specialists to bring cutting‑edge therapies to patients with chronic and malignant lung conditions.

Investigations into Immune System Phenomena aim to decipher how immune signatures influence response to therapy across multiple disease categories, supporting precision medicine initiatives.

• Phenotype‑guided selection of checkpoint inhibitors in solid tumors
• Correlation of peripheral immune cell subsets with remission in ulcerative colitis
• Impact of metabolic status on immune activation during combined cancer‑immunotherapy
• Longitudinal monitoring of immune reconstitution after hematologic stem‑cell transplantation

These projects leverage advanced immunoprofiling platforms to translate laboratory insights into actionable clinical strategies at the Potsdam site.